Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy
Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy: a Prospective, Multicenter, Observational Cohort Study
Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.
However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Suyue Pan, M.D., Ph.D.
- Phone Number: 13556184981
- Email: pansuyue@smu.edu.cn
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China
- Recruiting
- Fujian Medical University Union Hospital
-
Contact:
- Shenggen Chen, M.D.
- Phone Number: 13459480275
-
-
Guangdong
-
Dongguan, Guangdong, China
- Recruiting
- Dongguan People's Hospital
-
Contact:
- Zhu Shi, M.D.
- Phone Number: 13669825459
-
Dongguan, Guangdong, China
- Recruiting
- Dongguan donghua hospital
-
Contact:
- Lingyu Sun
- Phone Number: 13829203368
-
Guangzhou, Guangdong, China
- Recruiting
- Nanfang Hospital of Southern Medical University
-
Contact:
- Suyue Pan
- Phone Number: 13556184981
-
Guangzhou, Guangdong, China
- Recruiting
- Guangdong Provincial Hospital of Traditional Chinese Medicine
-
Contact:
- Lixin Wang, M.D.
- Phone Number: 13922793886
-
Guangzhou, Guangdong, China
- Recruiting
- Huadu District People's Hospital of Guangzhou
-
Contact:
- Guangning Li, M.D.
- Phone Number: 13926239656
-
Guangzhou, Guangdong, China
- Recruiting
- The Fourth Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Wangchi Luo, M.D.
- Phone Number: 13710895142
-
Heyuan, Guangdong, China
- Recruiting
- Heyuan people's Hospital
-
Contact:
- Minzhen Zhu
- Phone Number: 15007622318
-
Huizhou, Guangdong, China
- Recruiting
- Huizhou Municipal Central Hospital
-
Contact:
- Lizhi Wang, M.D.
- Phone Number: 13802872076
-
-
Hainan
-
Haikou, Hainan, China
- Recruiting
- Hainan Provincial People's Hospital
-
Contact:
- Fan Zhang, M.D.
- Phone Number: 17389897580
-
Haikou, Hainan, China
- Recruiting
- Haikou People's Hospital
-
Contact:
- Guoshuai Yang, M.D.
- Phone Number: 13876006248
-
Haikou, Hainan, China
- Recruiting
- Hainan Traditional Chinese Medicine Hospital
-
Contact:
- Yong Gu, M.D.
- Phone Number: 15521280288
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- The First Hospital of Changsha
-
Contact:
- Xu Peng, M.D。
- Phone Number: 15802507292
-
Hengyang, Hunan, China
- Recruiting
- The Second Hospital University of South China
-
Contact:
- Yanhong Hu, M.D.
- Phone Number: 13265004191
-
Yueyang, Hunan, China
- Recruiting
- Yueyang People's Hospital
-
Contact:
- Yuan Zhou, M.D.
- Phone Number: 15107309796
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China
- Recruiting
- Sinopharm North Hospital
-
Contact:
- Lifei Xing, M.D
- Phone Number: 15354919958
-
Hohhot, Inner Mongolia, China
- Recruiting
- The Affiliated Hospital of Inner Mongolia Medical University
-
Contact:
- Lihua Sun, M.D.
- Phone Number: 18686292585
-
-
Jiangxi
-
Ganzhou, Jiangxi, China
- Recruiting
- Ganzhou City People's Hospital
-
Contact:
- Zhaohui Lai
- Phone Number: 13879729792
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- Recruiting
- Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Saijun Zhou, M.D.
- Phone Number: 13857746659
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.
Description
Inclusion Criteria:
- Age ≥18 years.
- Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the "China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018".
- Meet the indications for mechanical thrombectomy in the "Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022".
- Treated with mechanical thrombectomy.
- NIHSS score ≥ 6 at onset of illness.
- Sign an informed notice.
Exclusion Criteria:
Allergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.
Have participated in other interventional clinical studies (affecting the outcome of this cohort study).
Participants who were judged by the investigator to be unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Stress Ulcer Prophylaxis
Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
|
Control Group
Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90-day mortality after onset
Time Frame: 90-day after onset
|
Proportion of enrolled patients who died 90 days after onset of disease. |
90-day after onset
|
|
Incidence of stroke-associated pneumonia
Time Frame: within 7-day of onset
|
Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset |
within 7-day of onset
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of clinically significant bleeding
Time Frame: within 7-day of onset
|
One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U. |
within 7-day of onset
|
|
Incidence of stress ulcer bleeding
Time Frame: 7-day after onset
|
Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood |
7-day after onset
|
|
Incidence of unfavorable functional prognosis at 90 days after onset
Time Frame: 90-day after onset
|
Incidence of unfavorable functional prognosis at 90 days after onset |
90-day after onset
|
|
90-day mRS score change
Time Frame: 90-day after onset
|
Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria |
90-day after onset
|
|
Incidence of early neurological deterioration
Time Frame: within 72 hours after onset
|
Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4 |
within 72 hours after onset
|
|
1-year post-onset mortality
Time Frame: 1 year after onset
|
Mortality at 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset
Time Frame: 1 year after onset
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Suyue Pan, Department of Neurology, Nanfang Hospital,Southern Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2023-040
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.